Clostridium difficile-associated disease in human stem cell transplant recipients: Coming epidemic or false alarm?

Bone Marrow Transplantation

Volumn 42, Issue 11, 2008, Pages 705-713

  Bobak, D ^a   Arfons, L M ^a   Creger, R J ^a   Lazarus, H M ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; BACITRACIN; CEPHALOSPORIN; CIPROFLOXACIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; COLESTYRAMINE; ENEMA; FUSIDIC ACID; IMMUNOGLOBULIN G; MACROLIDE; METRONIDAZOLE; NITAZOXANIDE; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN; TEICOPLANIN; TETRACYCLINE DERIVATIVE; TIACUMICIN B; TOLEVAMER; VANCOMYCIN;

ABDOMINAL CRAMP; BACTERIAL INFECTION; BACTERIAL STRAIN; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME IMMUNOASSAY; EPIDEMIC; FEVER; GASTROINTESTINAL SURGERY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION RISK; INTESTINE MOTILITY; LEUKOCYTOSIS; NEUTROPENIA; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ALGORITHMS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIARRHEA; ENTEROCOLITIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTESTINAL MUCOSA; RISK FACTORS; SPECIES SPECIFICITY;

EID: 58149467637     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.317     Document Type: Review

References (46)

1. Cloud J, Kelly CP. Update on Clostridium difficile associated disease. Curr Opin Gastroenterol 2007; 23: 4-9.
2. Owens Jr RC, Valenti AJ. Clostridium difficile-associated disease in the new millennium: 'the perfect storm' has arrived. Infect Dis Clin Pract 2007; 15: 299-315.
3. Blossom DB, McDonald LC. The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis 2007; 45 222-227.
4. Missaghi B, Valenti AJ, Owens Jr RC. Clostridium difficile infection: A critical overview. Curr Infect Dis Rep 2008; 10 165-173.
5. Monaghan T, Boswell T, Mahida YR. Recent advances in Clostridium difficile-associated disease. Gut 2008; 57: 850-860.
6. McDonald LC, Killgore GE, Thompson A, Owens Jr RC, Kazakova SV, Sambol SP et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433-2441.
7. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S et al A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-2449.
8. Bartlett JG. Narrative review: The new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006; 145: 758-764.
9. Owens RC. Clostridium difficile-associated disease: Changing epidemiology and implications for management. Drugs 2007; 67 487-502.
10. McMaster-Baxter NL, Musher DM. Clostridium difficile: Recent epidemiologic findings and advances in therapy. Pharmacotherapy 2007; 27: 1029-1039.
11. McFarland LV. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 40-48.
12. Jank T, Giesemann T, Aktories K. Rho-glucosylating Clostridium difficile toxins A and B: New insights into structure and function. Glycobiology 2007; 17: 15R-22R.
13. Genth H, Dreger SC, Huelsenbeck J, Just I. Clostridium difficile toxins: More than mere inhibitors of Rho proteins. Int J Biochem Cell Biol 2008; 40: 592-597.
14. Bobak DA. The molecular pathogenesis of Clostridium difficile associated disease. Curr Infect Dis Rep 2008; 10: 111-115.
15. Bustelo XR, Sauzeau V, Berenjeno IM. GTP-binding proteins of the Rho/Rac family: Regulation, effectors and functions in vivo. Bioessays 2007; 29: 356-370.
16. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett 2008; 582: 2093-2101.
17. Yolken RH, Bishop CA, Townsend TR, Bolyard EA, Bartlett J, Santos GW et al. Infectious gastroenteritis in bone-marrow transplant recipients. N Engl J Med 1982; 306: 1010-1012.
18. Cox GJ, Matsui SM, Lo RS, Hinds M, Bowden RA, Hackman RC et al. Etiology and outcome of diarrhea after marrow transplantation: A prospective study. Gastroenterology 1994; 107: 1398-1407.
19. Mossad SB, Longworth DL, Goormastic M, Serkey JM, Keys TF, Bolwell BJ. Early infectious complications in autologous bone marrow transplantation: A review of 219 patients. Bone Marrow Transplant 1996; 18: 265-271.
20. Yuen KY, Woo PC, Liang RH, Chiu EK, Chen FF, Wong SS et al. Clinical significance of alimentary tract microbes in bone marrow transplant recipients. Diagn Microbiol Infect Dis 1998; 30: 75-81.
21. Bilgrami S, Feingold JM, Dorsky D, Edwards RL, Bona RD, Khan AM. Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23: 1039-1042.
22. Avery R, Pohlman B, Adal K, Bolwell B, Goldman M, Kalaycio M et al High prevalence of diarrhea but infrequency of documented Clostridium difficile in autologous peripheral blood progenitor cell transplant recipients. Bone Marrow Transplant 2000; 25: 67-69.
23. Chakrabarti S, Lees A, Jones SG, Milligan DW. Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and nonrelapse mortality. Bone Marrow Transplant 2000; 26: 871-876.
24. van Kraaij MG, Dekker AW, Verdonck LF, van Loon AM, Vinjé J, Koopmans MP et al. Infectious gastro-enteritis: An uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients. Bone Marrow Transplant 2000; 26: 299-303.
25. Barton T, Collis T, Stadtmauer E, Schuster M. Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for the treatment of breast cancer. Clin Infect Dis 2001; 32: 391-395.
26. Gorschlüter M, Glasmacher A, Hahn C, Schakowski F, Ziske C, Molitor E et al. Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 2001; 33: 786-791.
27. Tomblyn M, Gordon L, Singhal S, Tallman M, Williams S, Winter J et al Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: Implications for symptomatic management of diarrhea. Bone Marrow Transplant 2002; 30: 517-519.
28. Jillella AP, Ustun C, Robach E, Sertkaya D, DiPiro C, Kallab AM et al Infectious complications in patients receiving mobilization chemotherapy for autologous peripheral blood stem cell collection. J Hematother Stem Cell Res 2003; 12: 155-160.
29. Arango JI, Restrepo A, Schneider DL, Callander NS, Ochoa-Bayona JL, Restrepo MI et al. Incidence of Clostridium difficile associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant 2006; 37: 517-521.
30. Balagopal A, Sears CL. Clostridium difficile: New therapeutic options. Curr Opin Pharmacol 2007; 7: 455-458.
31. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-307.
32. Kuijper EJ, Wilcox MH. Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection? Clin Infect Dis 2008; 47: 63-65.
33. Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008; 47: 56-62.
34. Bartlett JG. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46: 1489-1492.
35. Gerard L, Garey KW, DuPont HL. Rifaximin: A nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 2005; 3: 201-211.
36. Garey KW, Salazar M, Shah D, Rodrigue R, DuPont HL. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother 2008; 42: 827-835.
37. Bobak DA. Use of nitazoxanide for gastrointestinal tract infections: treatment of protozoan parasitic infection and beyond. Curr Infect Dis Rep 2006; 8: 91-95.
38. Musher DM, Logan N, Hamill RJ, Dupont HL, Lentnek A, Gupta A et al Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006; 43: 421-427.
39. Musher DM, Logan N, Mehendiratta V, Melgarejo NA, Garud S, Hamill RJ. Clostridium difficile colitis that fails conventional metronidazole therapy: Response to nitazoxanide. J Antimicrob Chemother 2007; 59: 705-710.
40. Maroo S, Lamont JT. Recurrent Clostridium difficile. Gastroenterology 2006; 130: 1311-1316.
41. Bobak DA. Clinical Trials Report: Nitazoxanide to treat persistent Clostridium difficile colitis. Curr Infect Dis Rep 2008; 10 89-90.
42. Bobak DA. Clinical Trials Report: Rifaximin to treat recurrent Clostridium difficile colitis. Curr Infect Dis Rep 2008; 10 90-91.
43. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44: 846-848.
44. Sebaihia M, Wren BW, Mullany P, Fairweather NF, Minton N, Stabler R et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 2006; 38: 779-786.
45. Carling PC, Parry MF, Von Beheren SM. Identifying opportunities to enhance environmental cleaning in 23 acute care hospitals. Infect Control Hosp Epidemiol 2008; 29: 1-7.
46. Dellit TH, Owens RC, McGowan Jr JE, Gerding DN, Weinstein RA, Burke JP et al. Infectious Diseases Society of America sand the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-177.